Medication info
Glucitaduo Extended Release Tablet 100/1000 mg

Glucitaduo Extended Release Tablet 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanol Bio Pharma Co., Ltd.
Appearance
Bright blue, oval extended-release film-coated tablet that is convex on both sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202020 · Approved 2022.05.13 · Insurance code 655605480

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication should be taken with food once daily, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. The 100/1000 mg extended-release tablet should be taken once daily as 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin regimen may start with 2 tablets of the 50/1000 mg extended-release formulation once daily. 3. Patients who do not achieve adequate glycemic control with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should take the patient’s blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.

Ingredients

Manufacturer
Hanol Bio Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication combines sitagliptin and metformin to aid blood sugar control in patients with type 2 diabetes. It helps improve blood sugar levels effectively while following dietary and exercise regimens. Therefore, it is used to facilitate better blood sugar management and to prevent the worsening of diabetes symptoms.

How to take

Adult dose

In antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication should be taken with food once daily, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. The 100/1000 mg extended-release tablet should be taken once daily as 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from concomitant therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin regimen may start with 2 tablets of the 50/1000 mg extended-release formulation once daily. 3. Patients who do not achieve adequate glycemic control with concomitant therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should take the patient’s blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.

Precautions

This medication contains both sitagliptin and metformin and is used for the treatment of type 2 diabetes. First, there may be allergic reactions while taking this medication, so if symptoms such as skin rashes, hives, or difficulty breathing occur, you should stop taking the medication immediately and consult a doctor. In addition, serious inflammation of the pancreas known as pancreatitis may occur, so if symptoms such as abdominal pain, nausea, vomiting, or fever arise, you must inform a healthcare professional immediately. Due to the metformin component, there is a rare but life-threatening risk of lactic acidosis. If symptoms such as severe fatigue, difficulty breathing, muscle pain, abdominal pain, or altered consciousness occur, you should go to the hospital immediately. If kidney function is poor, taking this medication may be risky, so regular kidney function tests should be conducted. If kidney function declines, the medication should be discontinued. Additionally, in cases of sudden dehydration, severe infections, heart diseases, or acute myocardial infarction, this medication should be avoided, and it should be temporarily discontinued around the time of surgery. This medication is not recommended for women who are pregnant or may become pregnant, or those who are breastfeeding. During treatment, symptoms of low blood sugar may occur, so if you experience dizziness, trembling, cold sweat, or confusion, you should immediately consume sugar. It is also important to eat regularly and avoid intense exercise or nutritional deficiencies. There may be interactions with other medications, so if you are taking any other drugs, you must inform your doctor or pharmacist. Finally, while taking this medication, regular blood tests and kidney function tests should be conducted, and it is advisable to periodically check vitamin B12 levels. It is safer to avoid alcohol while taking this medication.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemic episodes
  • hypoglycemic symptoms
  • anemia
  • severe hypoglycemia
  • decreased serum vitamin B12

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the drug's efficacy and safety for a longer period.

Appearance and packaging

Appearance

Bright blue, oval extended-release film-coated tablet that is convex on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.